Biomantissp. z o.o.
Overview
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 1 of 6 financial statements was filed late (for 2021, 91 days late).
- 2025not filed
- 202427/06/2025
- 202323/06/2024
- 202207/07/2023
- 202114/10/2022
- 202014/08/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Public procurement
3 tenders recorded as contractor, with a total value of $14,699.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Jul 23, 2025 | Pn 38/25 – supply of medicines, antibiotics, vaccines, compounded medicines, albumins and immunoglobulins outside the drug programme, and others – supplement and | $1,808$1,808 | Wojewódzki Szpital Specjalistyczny Im.J.Gromkowskiego | |
| Oct 30, 2024 | Supply of medicines – supplementary II (+ unresolved items + antibiotics + infusion solutions + vaccines + extemporaneous preparations + other) | $5,443$5,443 | Wojewódzki Szpital Specjalistyczny Im.J.Gromkowskiego | |
| Oct 28, 2024 | Supply of medicines – supplementary II (+ unresolved items + antibiotics + infusion solutions + vaccines + extemporaneous preparations + other) | $5,443$5,443 | Wojewódzki Szpital Specjalistyczny Im.J.Gromkowskiego |
Authorized Representatives
Manner of representation
To represent the company and make declarations of will on its behalf, in the case of a one-person management board, the President of the Management Board is authorized to act independently, whereas in the case of a multi-member management board, two members of the management board acting jointly or one member of the management board jointly with a commercial proxy are authorized.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 1,307 | $353,052.40 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $6,363.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 14, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $65$65 | URZĄD SKARBOWY KRAKÓW-PODGÓRZE | |
| Jun 12, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $6,154$6,154 | Polski Fundusz Rozwoju S.A. | |
| Dec 5, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $102$102 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | ||
| EIT Rawmaterials Clc Eastsp. z o.o. | $1,795,803.10 | eitrawmaterials.eu | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | ||
| Przedsiębiorstwo Wielobranżowe Genezasp. z o.o. | $54,163.54 | geneza.eu | ||
| Medtransfersp. z o.o. | $21,666.01 | codete.com | ||
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | ||
| Ncage TherapeuticsS.A. | $29.14 | ncage.org |
Change history
| Date | Event | |
|---|---|---|
| 2019-05-23 | Address change (Bobrzyńskiego 14, 30-348, Kraków → Ul. Podlesie 5/36, 30-667, Kraków) | |
| 2014-04-09 | Share capital increase (1,017,000.00 PLN → 1,307,000.00 PLN) | |
| 2013-09-09 | Entered in the register |
FAQ
Last updated: 2026-10-07